These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36500804)

  • 21. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
    Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
    Śmiłowicz D; Schlyer D; Boros E; Meimetis L
    Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
    J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Vallejo-Armenta P; Soto-Andonaegui J; Villanueva-Pérez RM; González-Díaz JI; Contreras-Contreras K; Bautista-Wong CG; Sandoval-Bonilla B; Nettel-Rueda B; Santos-Cuevas C; Ferro-Flores G
    Nucl Med Biol; 2021; 96-97():1-8. PubMed ID: 33640681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretherapeutic Comparative Dosimetry of
    Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
    J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
    Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiolabeling of PSMA-617 with
    Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
    Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 36. Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile.
    Deberle LM; Tschan VJ; Borgna F; Sozzi-Guo F; Bernhardt P; Schibli R; Müller C
    Molecules; 2020 May; 25(11):. PubMed ID: 32486054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and Biochemical Evaluation of Samarium-153 Oxide Nanoparticles Functionalized with iPSMA-Bombesin Heterodimeric Peptide.
    Trujillo-Benítez D; Ferro-Flores G; Morales-Avila E; Jiménez-Mancilla N; Ancira-Cortez A; Ocampo-García B; Santos-Cuevas C; Escudero-Castellanos A; Luna-Gutiérrez M; Azorín-Vega E
    J Biomed Nanotechnol; 2020 May; 16(5):689-701. PubMed ID: 32919488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Improved
    Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
    J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
    Das T; Guleria M; Parab A; Kale C; Shah H; Sarma HD; Lele VR; Banerjee S
    Nucl Med Biol; 2016 May; 43(5):296-302. PubMed ID: 27150032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.